{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:20:49Z","timestamp":1788366049654,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondi Ricerca Corrente"},{"DOI":"10.13039\/501100014835","name":"IRCCS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014835","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sacro Cuore Don Calabria Hospital"},{"name":"L. G."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tuberculosis treatment trials have used various comparison strategies. To inform trial design for novel tuberculosis regimens, we applied an existing framework for evaluating when uncontrolled trials might be justified. We conclude that the conditions are not met for tuberculosis treatment and that uncontrolled phase 3 trials should not be performed.<\/jats:p>","DOI":"10.1093\/cid\/ciag175","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:53:56Z","timestamp":1773233636000},"page":"e399-e403","source":"Crossref","is-referenced-by-count":0,"title":["When are Uncontrolled Trials in TB Scientifically and Ethically Justified: Borrowing Wisdom From Early AIDS Clinical Trials"],"prefix":"10.1093","volume":"83","author":[{"given":"Lindsay","family":"McKenna","sequence":"first","affiliation":[{"name":"Tuberculosis Project, Treatment Action Group , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3316-1930","authenticated-orcid":false,"given":"Mike","family":"Frick","sequence":"additional","affiliation":[{"name":"Tuberculosis Project, Treatment Action Group , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina A","family":"Alarc\u00f3n-Guizado","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Prevenci\u00f3n y Control de Tuberculosis, Direcci\u00f3n General de Intervenciones Estrat\u00e9gicas en Salud P\u00fablica, Ministerio de Salud , Lima ,","place":["Peru"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3819-490X","authenticated-orcid":false,"given":"Geraint R","family":"Davies","sequence":"additional","affiliation":[{"name":"Department of Clinical Infection, Microbiology and Immunology, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool , Liverpool ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J","family":"Furin","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-9635","authenticated-orcid":false,"given":"Lorenzo","family":"Guglielmetti","sequence":"additional","affiliation":[{"name":"Department of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital , Negrar di Valpolicella, Verona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9252-7106","authenticated-orcid":false,"given":"Norbert","family":"Heinrich","sequence":"additional","affiliation":[{"name":"German Center for Infection Research, Munich Partner Site, Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich , Munich ,","place":["Germany"]},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-2297","authenticated-orcid":false,"given":"Marcus","family":"Low","sequence":"additional","affiliation":[{"name":"Spotlight , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0782-1934","authenticated-orcid":false,"given":"Mariama","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"National Leprosy and Tuberculosis Control Program, Ministry of Health , Freetown ,","place":["Sierra Leone"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8509-4517","authenticated-orcid":false,"given":"Vidya","family":"Mave","sequence":"additional","affiliation":[{"name":"Johns Hopkins India Center for Infectious Diseases in India, , Pune ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Ndjeka","sequence":"additional","affiliation":[{"name":"School of Medicine, Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland ,","place":["USA"]},{"name":"National Department of Health , Pretoria ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-7024","authenticated-orcid":false,"given":"Patrick P J","family":"Phillips","sequence":"additional","affiliation":[{"name":"University of California SanFrancisco Center for Tuberculosis, University of California San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Schumacher","sequence":"additional","affiliation":[{"name":"Global Programme on Tuberculosis and Lung Health, World Health Organization , Geneva ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Harrington","sequence":"additional","affiliation":[{"name":"Treatment Action Group , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3455-658X","authenticated-orcid":false,"given":"Carole D","family":"Mitnick","sequence":"additional","affiliation":[{"name":"Department of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital , Negrar di Valpolicella, Verona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"2026090211575069500_ciag175-B1","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM199011083231912","article-title":"Design considerations for AIDS trials","volume":"323","author":"Byar","year":"1990","journal-title":"N Engl J Med"},{"key":"2026090211575069500_ciag175-B2","author":"World Medical Association"},{"key":"2026090211575069500_ciag175-B3","author":"World Health Organization"},{"key":"2026090211575069500_ciag175-B4","doi-asserted-by":"crossref","first-page":"e17601","DOI":"10.1371\/journal.pone.0017601","article-title":"Natural history of Tuberculosis: duration and fatality of untreated pulmonary Tuberculosis in HIV negative patients: a systematic review","volume":"6","author":"Tiemersma","year":"2011","journal-title":"PLoS One"},{"key":"2026090211575069500_ciag175-B5","author":"World Health Organization"},{"key":"2026090211575069500_ciag175-B6","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med"},{"key":"2026090211575069500_ciag175-B7","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang\u2019wa","year":"2022","journal-title":"N Engl J Med"},{"key":"2026090211575069500_ciag175-B8","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S2213-2600(25)00194-8","article-title":"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial","volume":"13","author":"Guglielmetti","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026090211575069500_ciag175-B9","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa2400327","article-title":"Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis","volume":"392","author":"Guglielmetti","year":"2025","journal-title":"N Engl J Med"},{"key":"2026090211575069500_ciag175-B10","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1473-3099(25)00218-X","article-title":"Treatment outcomes of bedaquiline-resistant tuberculosis: a retrospective and matched cohort study","volume":"25","author":"Mdlenyani","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026090211575069500_ciag175-B11","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/cid\/ciaf068","article-title":"Bedaquiline resistance and treatment outcomes among patients with tuberculosis previously exposed to bedaquiline in India: a multicentric retrospective cohort study","volume":"81","author":"Singla","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026090211575069500_ciag175-B12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1473-3099(25)00436-0","article-title":"A 3-month clofazimine\u2013rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial","volume":"26","author":"Metcalfe","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"2026090211575069500_ciag175-B13","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N Engl J Med"},{"key":"2026090211575069500_ciag175-B14","doi-asserted-by":"crossref","first-page":"146","DOI":"10.5588\/ijtld.12.0017","article-title":"Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis","volume":"17","author":"Horsburgh","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026090211575069500_ciag175-B15","doi-asserted-by":"crossref","first-page":"e007490","DOI":"10.1136\/bmjgh-2021-007490","article-title":"Recently developed drugs for the treatment of drug-resistant tuberculosis: a research and development case study","volume":"7","author":"Perrin","year":"2022","journal-title":"BMJ Glob Health"},{"key":"2026090211575069500_ciag175-B16","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"2026090211575069500_ciag175-B17","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1473-3099(24)00223-8","article-title":"Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial","volume":"24","author":"Cevik","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026090211575069500_ciag175-B18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1017\/9781108776301.016","volume-title":"The right to science","author":"Frick","year":"2021","edition":"1st ed"},{"key":"2026090211575069500_ciag175-B19","author":"Research, regulatory, and access considerations regarding pretomanid"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag175\/67339841\/ciag175.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/2\/e399\/67339841\/ciag175.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/2\/e399\/67339841\/ciag175.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:58:01Z","timestamp":1788364681000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/83\/2\/e399\/8519334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag175","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,15]]},"published":{"date-parts":[[2026,3,13]]}}}